Home › Breast Cancer › NCT05667532
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
Recruiting
Who can join
Ages 30 to 75 · Women
Full eligibility criteria
Inclusion Criteria: 1. Female patients 30-75 years of age with dense breasts (ACR BI-RADS categories C and D) who undergo routine yearly mammography at participating MDACC sites 2. Willingness to co-enroll or currently enrolled in PA17-0584 3. Willingness to participate in the study and ability to provide informed consent Exclusion Criteria: 1. Self-reported new breast symptoms since last mammogram including nipple discharge, palpable mass, skin dimpling, or focal pain. 2. Current or recent (within the prior 6 months) history of pregnancy or breast feeding 3. Personal history of breast cancer (DCIS or invasive breast cancer) 4. Treatment of any other type of cancer within the past 5 years excluding in-situ cervical and non-melanoma skin cancer 5. Breast biopsy within 6 months 6. Breast surgery within 12 months 7. Breast MRI, MBI, or CEM performed within 24 months 8. Known allergy to iodine-containing contrast agents 9. History of anaphylactic reaction to any substance that required hospitalization or IV placement in a patient with no known prior uneventful exposure to iodine-based IV contrast 10. Renal insufficiency (as defined by UTMDACC policy 3.30- attachment 1 (appendix D)
About the study
To learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts
What is being tested
- Contrast Enhanced Mammography (diagnostic test)
Sponsor: M.D. Anderson Cancer Center · Participants: 1,000 · Started: Dec 5, 2022
Contact the study team
- Olena Weaver, MD · Phone: (713) 745-4555
Official record on ClinicalTrials.gov — NCT05667532
Locations in the U.S.
| Texas | M D Anderson Cancer Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.